Results 41 to 50 of about 6,348 (189)

Maintenance therapy with a combination of azacitidine, danazol, and thalidomide after intensive chemotherapy in patients with acute myeloid leukemia

Hematology, 2023
Objective This study aimed to evaluate the efficacy of azacitidine (AZA) combined with danazol (DNZ) and thalidomide (THD) maintenance therapy after intensive chemotherapy (IC) in patients with acute myeloid leukemia (AML).Methods we retrospectively ...
Fang Zheng, Qianqian Li, Sisi Yang, Zhen Zhou, Qingfan Zeng, Kaiqi Liu   +5 more
doaj   +1 more source

Distinct clinical and genetic characteristics of myelodysplastic syndrome in younger patients

British Journal of Haematology, EarlyView.
Summary Myelodysplastic neoplasms (formerly myelodysplastic syndromes, MDS) are heterogeneous clonal haematological malignancies that primarily affect the elderly, though a notable proportion of patients are diagnosed at younger ages. We retrospectively analysed 1437 patients diagnosed or treated at Asan Medical Center between 1989 and 2022, comparing ...
Hyunkyung Park, Eun‐Ji Choi, Young‐Uk Cho, Yunsuk Choi, Han‐Seung Park, Jung‐Hee Lee, Joon Young Hur, Jisu Jeong, Seungah Cha, Yueun Lee, Young‐Shin Lee, Young‐Ah Kang, Mijin Jeon, Ji Min Woo, Hyeran Kang, Je‐Hwan Lee   +15 more
wiley   +1 more source

Efficacy of Danazol in Hematologic Disorders

, 1990
Danazol, an attenuated androgen developed for the treatment of endometriosis, has recently been found useful in the treatment of several hematologic disorders, including idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA ...
Ahn, Yeon S
core   +1 more source

Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY‐1 and MOMENTUM Trials

European Journal of Haematology, EarlyView.
In this post hoc analysis of the phase 3 SIMPLIFY‐1 and MOMENTUM trials, the number of patients with baseline hemoglobin < 10 g/dL who achieved hemoglobin ≥ 10 g/dL by week 24 with momelotinib, as well as the time to achievement, were evaluated. Patients who were JAK inhibitor naive and/or had moderate anemia were more likely and faster to achieve this
Francesca Palandri, Casey O'Connell, Pankit Vachhani, Donal P. McLornan, Steffen Koschmieder, Juan Carlos Hernandez‐Boluda, Kazuya Shimoda, Shiyuan Zhang, Catherine Ellis, Jessica Lim, Jasmine Sahni, Vikas Gupta   +11 more
wiley   +1 more source

Maternal nutrition as a key determinant of placental and developing blood–brain barrier xenobiotic protective functions

The Journal of Physiology, EarlyView.
Abstract figure legend Suboptimal maternal nutrition alters placental and developing blood–brain barrier (BBB) protective function and is associated with increased fetal brain vulnerability. In the placenta, nutritional adversity may reduce the exchange surface area and promote meta‐inflammation, compromising barrier efficiency in a model‐ and context ...
Kristin L. Connor, Nycolle I. S. Souza, Bruno G. Anjos, Stephen G. Matthews, Enrrico Bloise   +4 more
wiley   +1 more source

Hysteroscopic pictures following danazol therapy in endometrial hyperplasia

, 1987
Danazol is a synthetic steroid derived from ethisterone. Ten women with menometrorrhagia have been treated in order to demonstrate the modifications induced by Danazol on hyperplastic endometrium.
G. Marelli, S. Luchini, A. Tonta, M. A. Molinari, M. Busacca   +4 more
core   +2 more sources

Use of Cyclosporine A and danazol in treatment of aplastic anemia: A real-world data from a teaching hospital in South India

Asian Journal of Medical Sciences, 2022
Background: Due to financial constraints, there are limited treatment options for Aplastic anemia (AA) in developing countries. Aims and Objectives: In the present observational retrospective study, utility of Cyclosporine A (CsA) along with Danazol ...
Girish Kamat , Renukaradhya K Math , Deepak Goni , Girish Balikai , Ambuja Savanur , Nayana Mudennavar , Palaksha Kanive Javaregowda   +6 more
doaj   +1 more source

Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate‐to‐Severe Endometriosis Pain: A Phase III, Multicentric, Double‐Blind, Active‐Controlled, Non‐Inferiority Study

BJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 11, Page 2025-2034, October 2026.
ABSTRACT Objective To compare the efficacy, safety and tolerability of elagolix with dienogest in women with moderate‐to‐severe endometriosis‐associated pain. Design A multicentre, double‐blind, double‐dummy, randomised, parallel‐group, active‐controlled, non‐inferiority phase III study. Setting Nineteen clinical centres across India.
Sneha Bhoir, Jaldhara Patel, Tushar Palve, Mrinal Kanti Dash, Sweety Saigal, Gourisankar Kamilya, Shalini Srivastava, Kartikbhai Savalia, Tanusree Gupta, Deepa Choudhary, Manohar Rangaswamy, Vidya V Bhatt, Neena Gupta, Malathi Ponnuru, Parul Shah, Apurva Shetty, Shruti Saha, Reshma Quadros, Sucheta Pandit, Dipak Patil, Piyush Patel, Pravin Ghadge, Lalit Lakhwani, Suyog Mehta, Sadhana Joglekar   +24 more
wiley   +1 more source

The State of Shared Decision‐Making in Immune Thrombocytopenia: A Narrative Review and Health Care Provider Perspective

Health Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims Advances in the treatment of immune thrombocytopenia (ITP) have broadened the landscape of treatment options for patients. Shared decision‐making, a collaborative process between a patient and their health care team, is encouraged for these patients. The ultimate goal of shared decision‐making is to personalize treatment to
Shivi Jain, Kelsey Kuhel, Rose Cree, Michael D. Tarantino   +3 more
wiley   +1 more source

Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I‐WISh) 2.0

American Journal of Hematology, Volume 101, Issue 8, Page 1954-1968, August 2026.
ABSTRACT Limited data exist on how patients and physicians perceive immune thrombocytopenia (ITP) symptoms and treatment‐related burden. I‐WISh (ITP World Impact Survey) 2.0 surveyed 1018 patients and 431 physicians in 15 countries to characterize the impact of ITP and its treatments on patients.
Nichola Cooper, James Bussel, Waleed Ghanima, Drew Provan, Yoshiaki Tomiyama, Ming Hou, Donald M. Arnold, Cristina Santoro, Francesco Zaja, Barbara Lovrencic, Mervyn Morgan, Michal Winograd, Jennifer DiRaimo, Danielle Boyle, Olivera Rajkovic‐Hooley, Meritxell Vendranas, Susan Frade, Caroline Kruse   +17 more
wiley   +1 more source